Lipoprotein metabolism & CV risk: a long road from understanding to treatment

Media formats available:

Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
EAS 2024
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
- Evan Stein, MD, PhD
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
EAS 2024
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
EAS 2024
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
- Pasquale Perrone-Filardi, MD, PhD
ANGPTL3 RNAi therapeutic lowers atherogenic lipids and lipoproteins in patients with mixed hyperlipidemia
ANGPTL3 RNAi therapeutic lowers atherogenic lipids and lipoproteins in patients with mixed hyperlipidemia
EAS 2024
ANGPTL3 RNAi therapeutic lowers atherogenic lipids and lipoproteins in patients with mixed hyperlipidemia
- Robert S. Rosenson, MD

PACE-CME